Experience across
every stage.

Mr. Frohlich is the Chief Executive Officer and a member of the Jade Biosciences Board of Directors. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Business Officer at Chinook Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for strategy, business development, commercial planning, chemistry, manufacturing and controls, quality and program management.

From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Business Development at Inception Sciences, Inc., a drug discovery engine co-founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbutus Biopharma (formerly Tekmira Pharmaceuticals), a biopharmaceutical company, most recently as Vice President of Business Development from 2016 through 2018. Prior to joining Arbutus Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson, a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc., a pharmaceutical company, from 1998 through 2006, in various roles leading commercial strategy across all stages of product development.

Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.

Dr. King is Jade Biosciences’ Chief Scientific Officer & Head of Research and Development. Prior to his involvement in founding Jade, Dr. King served as Chief Scientific Officer at Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company that was acquired by Novartis AG, where he was responsible for overseeing the discovery research, non-clinical development, translational medicine and early clinical development teams, and played a lead role in late-stage clinical development strategy as chair or co-chair of the development review committee and as a sponsor representative on the company’s global Phase 3 clinical trial steering committees.  Prior to serving as Chief Scientific Officer, Dr. King served as Head of Renal Discovery and Translational Medicine for Chinook Therapeutics.Prior to joining Chinook, Dr. King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company, and as the Senior Director of Discovery and Translational Biology at Ardelyx, Inc. (Nasdaq: ARDX), a biotechnology company, where he focused on delivering small molecule candidates for the treatment of cardio-renal, metabolic and gastrointestinal diseases and made contributions to the approval of XPHOZAH® and IBSRELA®, including elucidating their novel mechanisms of action. Prior to Ardelyx, Inc., Dr. King was a Principal Research Scientist at AbbVie Inc. (NYSE: ABBV), where he led the Renal Discovery scientific strategy after serving in positions of increasing responsibility at Abbott Laboratories (NYSE: ABT).  Dr. King received a B.Sc. in Veterinary Biology from Murdoch University in Australia, a BVMS from Murdoch University in Australia and a Ph.D. in Pharmacology and Toxicology from Michigan State University.

Edward R. Conner, M.D., is the Chief Medical Officer of Jade Biosciences. He brings more than 20 years of experience in clinical development, translational medicine and regulatory strategy, with deep expertise in immunology and the advancement of mechanism-based therapies across early- to late-stage programs.

Prior to joining Jade, Dr. Conner served as Chief Medical Officer of Ardelyx, Inc. Prior to Ardelyx, Dr. Conner was Chief Medical Officer at Third Harmonic Bio. Previously, he was Chief Medical Officer at Locanabio. Earlier, he served as Site Lead and Division Head of Medical and Development at Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, Dr. Conner was Chief Medical Officer and Senior Vice President of Audentes Therapeutics, where he led clinical development and operations, medical affairs, regulatory, drug safety and patient advocacy. Before Audentes, he served as Chief Medical Officer of Sangamo Therapeutics, where he advanced multiple clinical programs across gene therapy, genome editing and cell therapy.

Earlier in his career, Dr. Conner was a Medical Director at Genentech, Inc. (a member of the Roche Group), where he led global clinical development programs for XOLAIR® (omalizumab) in chronic urticaria and allergic asthma.

He earned his M.D. from the University of California, San Francisco, completed his residency in internal medicine at the University of Michigan and a fellowship in clinical immunology and allergic diseases at Johns Hopkins School of Medicine. He holds a B.S. in biology from Duke University.

XOLAIR® is a registered trademark of Novartis AG.

Brad Dahms is the Chief Financial Officer of Jade Biosciences. He brings over 15 years of financial and strategic leadership experience across the biotechnology and investment banking sectors, with a focus on corporate finance, capital markets, and business development.

Prior to joining Jade, Mr. Dahms was Chief Financial Officer and Chief Business Officer of IDRx, where he led financial operations, investor relations, and business development, including its transition to a public-ready company and sale to GSK for up to $1.15 billion. Before that, he served as Chief Financial Officer of Theseus Pharmaceuticals, where he guided the company’s initial public offering and sale to Concentra Biosciences. Earlier, Mr. Dahms was Chief Financial Officer at Selecta Biosciences, where he played a central role in securing several financings and leading multiple strategic partnerships.

Mr. Dahms began his career in healthcare investment banking, holding roles at Cantor Fitzgerald, RBC Capital Markets, and J.P. Morgan. He earned a B.S. in Economics, with honors, from The Ohio State University.

Elizabeth Balta is the Chief Legal Officer and Corporate Secretary of Jade Biosciences. She most recently served as General Counsel of Icosavax, where she led all aspects of the company’s legal affairs from September 2021 until the acquisition of Icosavax by AstraZeneca in February 2024. Prior to joining Icosavax, Ms. Balta served as Associate General Counsel at Seagen Inc. from March 2016 to September 2021 where she helped lead and build the legal affairs group as Seagen transformed into a global, multi-product company.

Previously, she oversaw the legal function at Oncothyreon, Inc. where she handled a wide range of corporate, securities, clinical, manufacturing, licensing and transactional matters from 2012 to 2016. Prior to Oncothyreon, Ms. Balta served in roles of increasing responsibility at Emergent BioSolutions Inc. and Trubion Pharmaceuticals, Inc. from 2009 to 2012. Ms. Balta began her legal career as a corporate associate at Fenwick & West LLP and Orrick, Herrington Sutcliffe LLP where she advised early stage and public biopharmaceutical companies.

Ms. Balta received her J.D. from Harvard Law School and a B.A. in Human Biology from Stanford University.

Mr. Quick is the Senior Vice President of Finance at Jade Biosciences, bringing over 15 years of financial leadership in the biotechnology and pharmaceutical sectors. At Jade, he oversees the company’s finance, accounting, and treasury functions.

Prior to joining Jade, he led financial operations at Myeloid Therapeutics, managing key areas such as accounting and treasury. He also held a senior finance role at Alexion Pharmaceuticals, a subsidiary of AstraZeneca, where he directed finance and accounting for the genomic medicines division.

Previously, Mr. Quick played a key role at LogicBio Therapeutics, a Nasdaq-listed biotechnology company acquired by Alexion, overseeing public company reporting, financial planning, and the controllership function. Earlier in his career, he held roles of increasing responsibility at Karyopharm Therapeutics and Celldex Therapeutics. He began his career at PricewaterhouseCoopers LLP, working in the Deals Advisory practice.

Mr. Quick holds a B.S. in Accountancy from Providence College and is a Certified Public Accountant in Massachusetts.

Valerie Fauvelle is the Senior Vice President of Regulatory & Quality at Jade Biosciences. She brings nearly 25 years of experience in the biotech and pharma industries where she developed expertise in regulatory submissions, compliance frameworks, and quality oversight. Prior to joining Jade, she held leadership roles at several companies, including Chinook Therapeutics, where she guided regulatory strategy through clinical development and early commercialization as the SVP of Regulatory Affairs, interim head of Quality, head of Medical Writing and the Program Team Leader (PTL) for an early clinical asset.

Her career spans senior regulatory positions at Rainier Therapeutics, Cascadian Therapeutics (acquired by Seagen), Oncothyreon, Gilead Sciences, and ICOS Corporation, She began her career at Seattle Genetics and gained early healthcare experience as a Medical Technician at Phoenix Central Laboratory.

Ms. Fauvelle holds an M.S. in Clinical Research Administration from The George Washington University and a B.A. from the University of Washington.

Sandy Lewis is the Senior Vice President of Biometrics and Clinical Strategy at Jade Biosciences, bringing over 25 years of experience in biostatistics, clinical trial design, and global regulatory submissions. Most recently, she was Vice President of Biometrics at Chinook Therapeutics, where she built a high performing team and led biometrics strategy and clinical development.

Her career includes senior roles at Gilead Sciences, where she advanced from Senior Biostatistician to Director of Biostatistics as a statistical leader with expertise spanning across multiple therapeutic areas including respiratory, kidney and infectious diseases, and oncology.  She brings extensive knowledge of industry standards, driving innovative statistical designs and methodologies in regulatory submissions to uphold the highest standards of scientific rigor.

She holds a Master’s degree in Experimental Statistics from New Mexico State University and a Bachelor’s degree in Molecular Biology from the University of Oregon.

Amy Sullivan is the Senior Vice President of Development Operations at Jade Biosciences. A veteran drug development leader with nearly three decades of experience, Amy has a proven track record of delivering successful clinical programs from early development through post-approval.

Before joining Jade Biosciences, Amy served as the Senior Vice President of Development Operations at Alladapt Immunotherapeutics, where she helped build a world-class development organization while guiding the company’s clinical programs and operational strategy.

Earlier in her career, Amy worked as a clinical research coordinator in an HIV practice in San Francisco during the height of the AIDS epidemic. She then transitioned into the biopharma industry, working at BioMarin Pharmaceutical, Genentech, and Roche, where she ultimately led clinical portfolios and business process improvement initiatives across global clinical operations.

Amy holds a Bachelor’s degree in Biological Sciences from UC Santa Barbara.

Lori Stewart is the Senior Vice President of People at Jade Biosciences, bringing more than 25 years of experience in human resources leadership across biotechnology, financial services, and technology industries. She specializes in people strategy, organizational development, talent management, and fostering inclusive workplace cultures.

Before joining Jade Biosciences, Lori served as SVP, People and Culture at Icosavax, where she designed and led the company’s people and culture function, supporting organizational scale and the rapid progression of scientific programs from 2022 until the company’s acquisition by AstraZeneca in 2024. Prior to Icosavax, she was VP of People at Adaptive Biotechnologies, where she played a key role in early growth, and talent strategy.

Lori holds an MBA from Northeastern University and a BA in Management from Hartwick College.

Eric has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for up to $3.5 billion. Prior to Chinook, Mr. Dobmeier was President and CEO of Silverback therapeutics, and before that spent 16 years in a series of positions of increasing responsibility at Seattle Genetics, including Chief Operating Officer, during the company’s growth from 60 to 1,200 employees, from a market cap of $150 million to over $8 billion and through its transition to a commercial company with FDA approval and launch of Adcetris, a novel lymphoma drug. During his career, Mr. Dobmeier has been directly involved in raising more than $2 billion in equity capital and led negotiation of corporate alliances with many leading biotechnology and pharmaceutical companies. He is currently a venture partner at Samsara Biocapital and serves as a Board director for Structure Therapeutics and Janux Therapeutics, as well as several private biotechnology companies.

Chris Cain, Ph.D. is the Director of Research at Fairmount, a healthcare investment firm. Prior to joining Fairmount, Dr. Cain served in various positions at the healthcare funds Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Previously, Dr. Cain was a writer and editor at BioCentury Publications. He currently serves on the boards of Cogent Biosciences, Inc., Viridian Therapeutics, Inc., and Damora Therapeutics, Inc. He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.

Mr. Frohlich is the Chief Executive Officer and a member of the Jade Biosciences Board of Directors. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Business Officer at Chinook Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for strategy, business development, commercial planning, chemistry, manufacturing and controls, quality and program management.

From April 2018 to October 2023, Mr. Frohlich also served as an Operating Principal and subsequently as an Entrepreneur in Residence at Versant Ventures, a healthcare investment firm, where he was responsible for company creation and due diligence. From April 2018 to December 2018, Mr. Frohlich served as the Senior Vice President of Business Development at Inception Sciences, Inc., a drug discovery engine co-founded with Versant Ventures. Prior to joining Inception Sciences, from 2014 to 2018, Mr. Frohlich held positions of increasing responsibility at Arbutus Biopharma (formerly Tekmira Pharmaceuticals), a biopharmaceutical company, most recently as Vice President of Business Development from 2016 through 2018. Prior to joining Arbutus Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson, a pharmaceutical and medical technology company, from 2007 through 2014, and at Merck & Co., Inc., a pharmaceutical company, from 1998 through 2006, in various roles leading commercial strategy across all stages of product development.

Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.

Mr. Kiselak is a Founding Partner at Fairmount, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC. Mr. Kiselak serves as chairman of the board of directors of Viridian Therapeutics and Korsana Biosciences, and is a director for Spyre Therapeutics, and several private companies. He received his Bachelors in Neuroscience and Economics from Amherst College.

Dr. Klein is Chief Executive Officer of Oruka Therapeutics and a member of their Board of Directors. Before joining Oruka, he was a Partner at Versant Ventures, where he invested in and helped grow early-stage biotechnology companies. He previously was a member of the CRISPR Therapeutics leadership team and helped grow the company into one of the most recognized innovative biotechnology companies in the industry. During his seven-year tenure with CRISPR, he served as Chief Business Officer before also taking on the role of Chief Operating Officer. In these roles he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs, and contribute to building the team. Prior to CRISPR, he served a variety of clients in the biopharma industry as an Associate Partner at McKinsey & Company. He currently serves as a member of the Jade Biosciences Board of Directors.

Dr. Klein holds a PhD in biophysics from Stanford University, where his research focused on T cell immunology.

Erin Lavelle is an accomplished biopharma executive with over 25 years of strategic and operational leadership experience in the biopharmaceutical industry. Most recently as the chief operating officer and chief financial officer of ProfoundBio, Ms. Lavelle led the company’s $1.8 billion acquisition by Genmab and the $112 million oversubscribed Series B financing preceding the acquisition, and spearheaded the company’s public company readiness efforts. Before joining ProfoundBio, Ms. Lavelle served as chief operating officer and chief financial officer at Eliem Therapeutics, where she executed a combined $150 million Series B financing and initial public offering. Prior to Eliem, Ms. Lavelle was the chief operating officer at Alder BioPharmaceuticals, where she led the company’s $2.3 billion acquisition by H. Lundbeck A/S. Prior to Alder, she held a variety of roles of increasing responsibility during 15 years at Amgen and was a healthcare investment banker at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of the board of directors of Avalyn Pharma Inc., as well as several private companies. She received her BA in Economics from Yale University.

Dr. Eisner is a biotechnology executive with extensive experience in global clinical development and regulatory strategy across multiple therapeutic areas. He most recently served as Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc., where he oversaw clinical development, regulatory sciences and medical affairs.

Prior to joining Vir Bio, he served as Chief Medical Officer at Sonoma Biotherapeutics and FibroGen, Inc. (now known as Kyntra Bio, Inc.), and as a Scientific Advisory Board member for Aer Therapeutics. Earlier in his career, he spent nearly 11 years at Genentech/Roche, where he held positions of increasing responsibility, including Senior Vice President and Global Head of Product Development for Immunology, Infectious Disease, and Ophthalmology.

Dr. Eisner serves as a board director for Zura Bio Limited.

Prior to entering the biopharmaceutical industry, Dr. Eisner was Professor of Medicine and Anesthesia at University of California, San Francisco. Dr. Eisner holds an AB degree in Human Biology from Stanford University, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MPH focused on epidemiology from University of California, Berkeley School of Public Health.